Evidence map›Paper›PMID 37351834›Full record

ArticleMolecular biotechnology2024

Structure-Based Virtual Screening and Discovery of New Bi-functional DAPK1 Inhibitors.

Priti Talwar, Pratibha Singh, Palaniyandi Ravanan

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 4 citations in OpenAlex.

  1. Review
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 2 institutions in 1 country.

Priti TalwarApoptosis and Cell Survival Research Laboratory, Department of Biosciences, School of Biosciences and Technology, Vellore Institute of Technology, 412G Pearl Research Park, Vellore, Tamil Nadu, 632014, India. priti.t@vit.ac.in.ORCID http://orcid.org/0000-0002-6826-581X
Pratibha SinghApoptosis and Cell Survival Research Laboratory, Department of Biosciences, School of Biosciences and Technology, Vellore Institute of Technology, 412G Pearl Research Park, Vellore, Tamil Nadu, 632014, India.
Palaniyandi RavananFunctional Genomics Laboratory, Department of Microbiology, Central University of Tamil Nadu, Thiruvarur, Tamil Nadu, 610005, India. ravanan@cutn.ac.in.ORCID http://orcid.org/0000-0003-0665-5801
Vellore Institute of Technology University · INCentral University of Tamil Nadu · IN

Funding

Science and Engineering Research Board YSS/2014/000915
6 · The paper itself

Abstract

Recently, a new signaling complex Death-Associated Protein Kinase 1 (DAPK1)-N-methyl D-aspartate receptor subtype 2B (NR2B) engaged in the neuronal death cascade was identified where it was found that after stroke injury, N-methyl-D-aspartate glutamate (NMDA) receptors interact with DAPK1 through NR2B subunit and lead to excitotoxicity via overactivation of NMDA receptors. In this study, we used ZINC-12 database to find out potential inhibitor of DAPK1 and found some natural compounds showing good binding affinity towards DAPK1. These natural compounds showed interactions with ATP-binding site residues as well as substrate-recognition motifs. Thus, it has been concluded that the ligands those are showing interactions with both the sites could be considered as potential inhibitors for DAPK1.

Indexed as

Death-Associated Protein KinasesProtein Kinase InhibitorsBinding SitesDrug DiscoveryHumansLigandsMolecular Docking SimulationProtein BindingReceptors, N-Methyl-D-AspartateDAPK1 protein, humanDeath-Associated Protein KinasesLigandsNR2B NMDA receptorProtein Kinase InhibitorsReceptors, N-Methyl-D-AspartateDAPK1Molecular dynamicsNMDA receptorsSubstrate-recognition motifsZinc-12

Identifiers

PMID37351834
OpenAlexW4381715842

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.